Show simple item record

Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy

dc.contributor.authorMarkan, K.
dc.contributor.authorSaeed, A.
dc.contributor.authorHamza, M.A.
dc.contributor.authorVyfhuis, M.A.L.
dc.contributor.authorScilla, K.
dc.contributor.authorMehra, R.
dc.contributor.authorRolfo, C.
dc.contributor.authorMohindra, P.
dc.date.accessioned2022-04-05T20:18:51Z
dc.date.available2022-04-05T20:18:51Z
dc.date.issued2021-11
dc.identifier.urihttp://hdl.handle.net/10713/18473
dc.description.abstractThe degree of lymphopenia has been linked with negative impact on outcomes in patients undergoing radiation therapy (RT) for stage III non-small cell lung cancer (NSCLC). Proton therapy, by virtue of reducing integral dose, can possibly help mitigate risk of lymphopenia as demonstrated in patients with glioblastoma and esophageal cancer. This study sought to analyze the effects of intensity modulated proton therapy (IMPT) in limiting degree of lymphopenia in patients with stage III NSCLC when compared to those treated with photon-based volumetric-modulated arc therapy (VMAT).en_US
dc.description.urihttps://doi.org/10.1016/j.ijrobp.2021.07.1263en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physicsen_US
dc.rightsCopyright © 2021 Published by Elsevier Inc.en_US
dc.rights.urihttps://www.elsevier.com/tdm/userlicense/1.0/
dc.titleLymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapyen_US
dc.typeAbstracten_US
dc.identifier.doi10.1016/j.ijrobp.2021.07.1263
dc.source.journaltitleInternational Journal of Radiation Oncology*Biology*Physics
dc.source.volume111
dc.source.issue3
dc.source.beginpagee447
dc.source.endpagee448


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record